Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II trial of Rifamycin SV-MMX in IBS-D
2016-004977-42Phase 2Completed
- Sponsor
- Cosmo Pharmaceuticals
- Start
- Jun 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of rifamycin SV-MMX in irritable bowel syndrome (IBS) (3 arms), sponsored by Cosmo Pharmaceuticals. Primary endpoint: Proportion of weekly responders for composite abdominal pain and stool consistency relief. Started Jun 2017; status: completed.
02
Drugs
rifamycin SV-MMX
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on 2016-004977-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004977-42.